Loading clinical trials...

Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents | Clinical Trials | Clareo Health

RECRUITINGPHASE1/PHASE2

Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents

A Double-blinded, Randomized, Parallel, Placebo-controlled Trial of Wharton's Jelly-derived Allogeneic Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents

NCT05061030•Uppsala University Hospital

View on ClinicalTrials.gov

Summary

This is a combined phase 1 and 2 study in 66 subjects, male or female, between 7-21 years of age that have recently (\< 6 months) been diagnosed with type 1 diabetes. The first phase 1 part of the study includes six subjects openly receiving allogeneic Wharton's jelly derived mesenchymal stromal cells as the Advanced Therapy Medicinal Product (ATMP) Protrans, three each in the age ranges 7-11 and 12-18.The second part is a randomized, double-blinded placebo-controlled phase 2 study in parallel design comparing allogeneic Wharton's jelly derived mesenchymal stromal cells treatment (as Protrans) to placebo in children and adolescent subjects (7-21 years of age) diagnosed with type 1 diabetes, The primary objectives of this study will be to investigate the safety, tolerance and efficacy after an allogieneic infusion of Wharton's jelly derived mesenchymal stromal cells.

Eligibility

Age

7 - 21 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Written informed consent for participation of the study (for subjects below 18 years of age also from both caregivers), given before undergoing any study-specific procedures
•2. Clinical history compatible with type 1 diabetes diagnosed less than 6 months before enrolment
•3. In the first part of the study, six subjects, three between 7-11 and three between 12-18 years of age (both groups inclusive at both ends), will be included. The sixty subjects in the second part of the study are stratified by age (12-21 and 7-11 years, respectively) and randomized to one of two treatment arms (active or placebo), with a 6-month safety delay for the younger stratum.
•4. Mentally stable and, in the opinion of the investigator, able to comply with the procedures of the study protocol.
•5. Fasting plasma C-peptide concentration \>0.12 nmol/L.
•6. Subjects of child-bearing potential must agree to using adequate contraception until one year after the administration of WJMSC/Placebo. Adequate contraception is as follows:
•1. oral (except low-dose gestagen (lynestrenol and noretisteron), injectable or implanted hormonal contraceptives.
•2. intrauterine device
•3. intrauterine system (for example progestin-releasing coil)
•4. vasectomized male (with appropriate postvasectomy documentation of the absence of sperm in the ejaculate)

Exclusion Criteria

•1. Subjects with body weight \>100 kg
•2. Subjects with unstable cardiovascular status incl. NYHA class III/IV or symptoms of angina pectoris.
•3. Subjects with uncontrolled hypertension (≥160/105 mmHg).
•4. Subjects with active on-going infections.
•5. Subjects with latent or previous as well as on-going therapy against tuberculosis, or exposed to tuberculosis or has traveled in areas with a high risk of tuberculosis or mycosis within the last 3 months.
•6. Subjects with serological evidence of infection with HIV, Treponema pallidum, hepatitis B antigen (subjects with serology consistent with previous vaccination and a history of vaccination are acceptable), or hepatitis C.
•7. Subjects with any systemic immune suppressive treatment
•8. Subjects with a known demyelinating disease or with symptoms or physical examination findings consistent with possible demyelinating disease.
•9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
•10. Subjects with known, or previous, malignancy.
+4 more criteria

Locations (1)

Uppsala University Hospital

Uppsala, Sweden

Key Dates

Start Date

January 14, 2022

Primary Completion Date

September 1, 2028

Completion Date

December 1, 2028

Last Updated

December 5, 2024

Enrollment

ESTIMATED participants

Conditions

Type1diabetes

Interventions

the ATMP Protrans

BIOLOGICAL

Contacts

Per-Ola Carlsson, MD, PhD

CONTACT

+46186110000 per-ola.carlsson@mcb.uu.se

Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children

NCT05054361

Type1diabetes

View study

RECRUITINGPHASE1

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

NCT06753994

DiabetesType1diabetes+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 5, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents

Inclusion Criteria

Exclusion Criteria

Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children

Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors

Screening for Islet Autoantibodies in the Israeli Paediatric General Population for Detection of Pre-symptomatic Type-1 Diabetes Mellitus

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

Advanced Glycation Products and Vascular Complications in Type 1 Diabetes

Observational Study of the Use of DBLG1 System in Real Life